{"acute kidney injury": 7.57, "anaemia": 5.18, "atypical haemolytic uraemic syndrome": 118.91, "cardiac failure": 9.32, "cardiotoxicity": 17.56, "covid-19 pneumonia": 5.33, "cytokine release syndrome": 2.84, "cytopenia": 14.59, "disease progression": 3.1, "ejection fraction decreased": 7.49, "febrile neutropenia": 5.84, "haemolytic anaemia": 9.85, "hypokalaemia": 3.65, "infection": 2.83, "infusion related reaction": 6.75, "intentional product use issue": 12.25, "leukopenia": 3.66, "lymphopenia": 6.64, "microangiopathic haemolytic anaemia": 141.56, "mucosal inflammation": 4.09, "multiple organ dysfunction syndrome": 4.02, "myelosuppression": 4.19, "neuropathy peripheral": 4.99, "neutropenia": 4.58, "neutrophil count decreased": 2.43, "off label use": 6.48, "pancytopenia": 6.22, "plasma cell myeloma": 260.29, "plasma cell myeloma recurrent": 295.18, "plasma cell myeloma refractory": 379.2, "plasmacytoma": 171.37, "platelet count decreased": 3.7, "pleural effusion": 3.51, "pneumonia": 4.14, "progressive multifocal leukoencephalopathy": 19.65, "pulmonary arterial hypertension": 6.42, "pulmonary hypertension": 6.39, "pulmonary oedema": 3.05, "renal failure": 3.17, "respiratory failure": 3.39, "sepsis": 4.69, "septic shock": 2.59, "therapeutic product effect incomplete": 4.61, "therapy non-responder": 19.96, "therapy partial responder": 63.65, "thrombocytopenia": 8.69, "thrombotic microangiopathy": 99.53, "tumour lysis syndrome": 38.66}